About: The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study
Creator	Puren, Adrian Barnhart, Scott Gilmore, Hailey Grignon, Jessica Hunt, Gillian Liegler, Teri Lippman, Sheri Mooney, Alyssa Prach, Lisa Truong, Hong-Ha
Source	PMC
abstract	BACKGROUND: Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective. We examine the contribution of drug resistance mutations for low viral suppression in HIV-positive participants in a population-based sero-prevalence survey in rural South Africa. METHODS: We conducted HIV drug resistance genotyping and ART analyte testing on dried blood spots (DBS) from HIV-positive adults participating in a 2014 survey in North West Province. Among those with virologic failure (> 5000 copies/mL), we describe frequency of DRM to protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI), report association of resistance with antiretroviral therapy (ART) status, and assess resistance to first and second line therapy. Analyses are weighted to account for sampling design. RESULTS: Overall 170 DBS samples were assayed for viral load and ART analytes; 78.4% of men and 50.0% of women had evidence of virologic failure and were assessed for drug resistance, with successful sequencing of 76/107 samples. We found ≥1 DRM in 22% of participants; 47% were from samples with detectable analyte (efavirenz, nevirapine or lopinavir). Of those with DRM and detectable analyte, 60% showed high–level resistance and reduced predicted virologic response to ≥1 NRTI/NNRTI typically used in first and second-line regimens. CONCLUSIONS: DRM and predicted reduced susceptibility to first and second-line regimens were common among adults with ART exposure in a rural South African population-based sample. Results underscore the importance of ongoing virologic monitoring, regimen optimization and adherence counseling to optimize durable virologic suppression.
has issue date	2020-03-26(xsd:dateTime)
bibo:doi	10.1186/s12879-020-4933-z
bibo:pmid	32216752
has license	cc-by
sha1sum (hex)	5484436a32fa87a1bcf03c41e8e224a0c2e0515e
schema:url	https://doi.org/10.1186/s12879-020-4933-z
resource representing a document's title	The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study
has PubMed Central identifier	PMC7099808
has PubMed identifier	32216752
schema:publication	BMC Infect Dis
resource representing a document's body	covid:5484436a32fa87a1bcf03c41e8e224a0c2e0515e#body_text
is schema:about of	named entity 'viral' named entity 'study' named entity 'REMAINS' named entity 'UNDERSTANDING' named entity 'effective' named entity 'DRM' named entity 'viral load' named entity 'run the risk' named entity 'drug resistance' named entity 'virally' named entity 'PrEP' named entity 'ABC' named entity 'sero' named entity 'rural South' named entity 'HIV' named entity 'viruses' named entity 'acquired resistance' named entity 'antiretroviral' named entity 'South Africa' named entity 'acquired resistance' named entity 'NIH' named entity 'TDF' named entity 'virologic failure' named entity 'analyte' named entity 'medication adherence' named entity 'TDF' named entity 'peri-urban areas' named entity 'HIV-positive status' named entity 'systematic review' named entity 'KwaZulu-Natal' named entity 'desiccant' named entity 'codons' named entity 'HIV' named entity 'codons' named entity 'NNRTI' named entity 'reverse-transcriptase inhibitor' named entity 'analyte' named entity 'HIV' named entity 'Emergency Plan for AIDS Relief' named entity 'Western blot' named entity 'acquired resistance' named entity 'analyte' named entity 'Japan' named entity 'PCR' named entity 'general population' named entity 'South Africa' named entity 'genotyping' named entity 'antiretroviral drug' named entity 'Stata' named entity 'NRTI' named entity 'abacavir' named entity 'analyte' named entity 'acute HIV infection' named entity 'drug resistance' named entity 'NRTI' named entity 'burden of disease' named entity 'virological' named entity 'Lekwa-Teemane' named entity 'South Africa' named entity 'NRTI' named entity 'HIV' named entity 'population-based sample' named entity 'NNRTIs' named entity 'Africa' named entity 'ARV' named entity 'testing laboratory' named entity 'Setswana' named entity 'morbidity' named entity 'NNRTI' named entity 'DBS' named entity 'liquid chromatography' named entity 'Greater Taung'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software